These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 32070682)

  • 1. Tdap vaccination during pregnancy interrupts a twenty-year increase in the incidence of pertussis.
    Langsam D; Anis E; Haas EJ; Gosinov R; Yechezkel M; Grotto I; Shmueli E; Yamin D
    Vaccine; 2020 Mar; 38(12):2700-2706. PubMed ID: 32070682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Seroprevalence of Bordetella pertussis antibodies and anti-pertussis antibody response after a single dose of reduced-antigen combined diphtheria, tetanus, and acellular pertussis vaccine (Tdap) in pregnant Thai women.
    Sompagdee N; Anuwutnavin S; Phongsamart W; Senawong S; Umrod P; Robkhonburi A
    Vaccine; 2020 Mar; 38(12):2725-2733. PubMed ID: 32070680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maternal pertussis vaccination and its effects on the immune response of infants aged up to 12 months in the Netherlands: an open-label, parallel, randomised controlled trial.
    Barug D; Pronk I; van Houten MA; Versteegh FGA; Knol MJ; van de Kassteele J; Berbers GAM; Sanders EAM; Rots NY
    Lancet Infect Dis; 2019 Apr; 19(4):392-401. PubMed ID: 30938299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
    America Academy of Pediatrics Commitee on Infectious Diseases
    Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing the reactogenicity of Tdap vaccine administered during pregnancy and antibodies to Bordetella pertussis antigens in maternal and cord sera of Thai women.
    Wanlapakorn N; Maertens K; Chaithongwongwatthana S; Srimuan D; Suratannon N; Vongpunsawad S; Tran TMP; Hens N; Van Damme P; Locht C; Poovorawan Y; Leuridan E
    Vaccine; 2018 Mar; 36(11):1453-1459. PubMed ID: 29426663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study.
    Kovac M; Kostanyan L; Mesaros N; Kuriyakose S; Varman M
    Hum Vaccin Immunother; 2018; 14(8):1977-1986. PubMed ID: 29630439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults.
    Brandon D; Kimmel M; Kuriyakose SO; Kostanyan L; Mesaros N
    Vaccine; 2018 Oct; 36(42):6325-6333. PubMed ID: 30197282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.
    Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A;
    Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review of the burden of pertussis disease in infants and the effectiveness of maternal immunization against pertussis.
    Kandeil W; van den Ende C; Bunge EM; Jenkins VA; Ceregido MA; Guignard A
    Expert Rev Vaccines; 2020 Jul; 19(7):621-638. PubMed ID: 32772755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model.
    Kwon HJ; Han SB; Kim BR; Kang KR; Huh DH; Choi GS; Ahn DH; Kang JH
    BMC Infect Dis; 2017 Apr; 17(1):247. PubMed ID: 28376777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody responses after primary immunization in infants born to women receiving a pertussis-containing vaccine during pregnancy: single arm observational study with a historical comparator.
    Ladhani SN; Andrews NJ; Southern J; Jones CE; Amirthalingam G; Waight PA; England A; Matheson M; Bai X; Findlow H; Burbidge P; Thalasselis V; Hallis B; Goldblatt D; Borrow R; Heath PT; Miller E
    Clin Infect Dis; 2015 Dec; 61(11):1637-44. PubMed ID: 26374816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of timing of maternal combined tetanus, diphtheria, and acellular pertussis (Tdap) immunization and protection of young infants.
    Healy CM; Rench MA; Baker CJ
    Clin Infect Dis; 2013 Feb; 56(4):539-44. PubMed ID: 23097585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Broder KR; Cortese MM; Iskander JK; Kretsinger K; Slade BA; Brown KH; Mijalski CM; Tiwari T; Weston EJ; Cohn AC; Srivastava PU; Moran JS; Schwartz B; Murphy TV;
    MMWR Recomm Rep; 2006 Mar; 55(RR-3):1-34. PubMed ID: 16557217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acellular pertussis vaccine use in risk groups (adolescents, pregnant women, newborns and health care workers): a review of evidences and recommendations.
    Bechini A; Tiscione E; Boccalini S; Levi M; Bonanni P
    Vaccine; 2012 Jul; 30(35):5179-90. PubMed ID: 22709953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. US Infant Pertussis Incidence Trends Before and After Implementation of the Maternal Tetanus, Diphtheria, and Pertussis Vaccine.
    Skoff TH; Deng L; Bozio CH; Hariri S
    JAMA Pediatr; 2023 Apr; 177(4):395-400. PubMed ID: 36745442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced-antigen, combined diphtheria-tetanus-acellular pertussis vaccine, adsorbed (Boostrix) US formulation): use as a single-dose booster immunization in adolescents aged 10-18 years.
    Frampton JE; Keam SJ
    Paediatr Drugs; 2006; 8(3):189-95; discussion 196. PubMed ID: 16774298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Whooping cough in Spain. Current epidemiology, prevention and control strategies. Recommendations by the Pertussis Working Group].
    Campins M; Moreno-Pérez D; Gil-de Miguel A; González-Romo F; Moraga-Llop FA; Arístegui-Fernández J; Goncé-Mellgren A; Bayas JM; Salleras-Sanmartí L
    Enferm Infecc Microbiol Clin; 2013 Apr; 31(4):240-53. PubMed ID: 23411362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humoral immunity 10 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine in the USA.
    Pool V; Tomovici A; Johnson DR; Greenberg DP; Decker MD
    Vaccine; 2018 Apr; 36(17):2282-2287. PubMed ID: 29573876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole-Cell or Acellular Pertussis Primary Immunizations in Infancy Determines Adolescent Cellular Immune Profiles.
    van der Lee S; Hendrikx LH; Sanders EAM; Berbers GAM; Buisman AM
    Front Immunol; 2018; 9():51. PubMed ID: 29416544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Prepregnancy Pertussis Vaccination in Young Infants.
    Maertens K; Tran TMP; Hens N; Van Damme P; Leuridan E
    J Infect Dis; 2017 Jun; 215(12):1855-1861. PubMed ID: 28863468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.